Ireland - English - HPRA (Health Products Regulatory Authority)

hikma farmaceutica (portugal) sa - bicalutamide - film coated tablet - 50 milligram - anti-androgens

European Union - English - EMA (European Medicines Agency)

hikma farmaceutica (portugal) s.a. - voriconazole - bacterial infections and mycoses; aspergillosis; candidiasis - antimycotics for systemic use - voriconazole is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of candidaemia in non-neutropenic patients;treatment of fluconazole-resistant serious invasive candida infections (including c. krusei);treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections.prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct)recipients.

Malta - English - Medicines Authority

hikma farmacêutica (portugal),sa estrada do rio da mó, 8, 8a e 8b, fervença, terrugem, snt, 2705-906, portugal - caspofungin acetate - powder for concentrate for solution for infusion - caspofungin acetate 50 mg - antimycotics for systemic use

Malta - English - Medicines Authority

hikma farmacêutica (portugal),sa estrada do rio da mó, 8, 8a e 8b, fervença, terrugem, snt, 2705-906, portugal - caspofungin acetate - powder for concentrate for solution for infusion - caspofungin acetate 70 mg - antimycotics for systemic use

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

hikma pharmaceuticals plc, jordan - midazolam - solution for injection - 5 mg/ml

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

alhayat pharmaceuticals portugal - 3ml ampoule x 5 - injection - 5mg/ml - anaesthesia-general anaesthesia

Ireland - English - HPRA (Health Products Regulatory Authority)

hikma farmacêutica (portugal) s.a. - teicoplanin - powder for solution for injection/infusion - 200 milligram(s) - glycopeptide antibacterials; teicoplanin

Ireland - English - HPRA (Health Products Regulatory Authority)

hikma farmacêutica (portugal) s.a. - teicoplanin - powder for solution for injection/infusion - 400 milligram(s) - glycopeptide antibacterials; teicoplanin

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 250 mg in 50 ml - levofloxacin injection is indicated for the treatment of adults (≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus , pseudomonas aeruginosa , serratia marcescens , escherichia coli , klebsiella pneumoniae , haemophilus influenzae , or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1) ]. levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible sta

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin injection is indicated for the treatment of adults (≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus , pseudomonas aeruginosa , serratia marcescens , escherichia coli , klebsiella pneumoniae , haemophilus influenzae , or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1) ]. levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible sta